Introduction
Epilepsy is one of the most common and severe neurological diseases in the world. It is also an important cause of mortality and disability in developing countries. Nearly 85% of the epilepsy load in the world can be found in developing countries, where the majority of patients with epilepsy do not receive appropriate medical care. Epidemiological studies show a higher prevalence and incidence of this condition in the general population of Latin American than in the North American countries. 1 A recent population study in a rural Mexican community found a 3.9/ 1000 prevalence of epilepsy. 2 The prognosis for most patients with epilepsy is in general good, but up to 30% persist with seizures in spite of being treated with adequate antiepileptic drugs (AEDs);
this produces important harmful effects in the individual's health and quality of life, and it also represents a considerable burden for society. 3 The terms adverse event (AE) or adverse experience are used interchangeably in order to describe the presence of an undesirable effect in the patient during pharmacological treatment. An adverse event due to medication, as defined by the Food and Drug Administration (FDA), means ''any adverse event associated with the use of a drug in humans, whether or not considered drug related, including the following: an adverse event occurring in the course of the use of a drug product in professional practice or study; an adverse event occurring from drug overdose; an adverse event occurring from drug withdrawal; and any failure of expected pharmacological action''. 4 After evaluating the negative effects of AEDs on general health and quality of life, the Commission on Outcome Measurement from the International League Against Epilepsy (ILAE) recommended incorporating reliable and valid tools (instruments) in clinical essays in order to achieve a more accurate assessment of the subjective AEs rate and disease severity when using AEDs.
After reviewing the negative effects of antiepileptic drugs (AEDs) on general health and quality of life, the Commission on Outcome Measurement from the International League Against Epilepsy (ILAE) recommended incorporating reliable and valid tools in clinical essays in order to achieve a more accurate assessment of the subjective adverse effects rate and disease severity when using AEDs. Purpose: The aim of this study was to correlate the severity of adverse effects of AEDs, with the presence of anxiety and depression in patients with epilepsy. Methods: The Spanish version of the Liverpool Adverse Events Profile (LAEP) and the Hospital Anxiety and Depression Scale (HADS) were applied on 130 consecutive outpatients with epilepsy from the epilepsy clinic at the Mexico's National Institute of Neurology and Neurosurgery. A correlation analysis was carried out to determine if the presence of depression and anxiety was related to the adverse effects of AEDs. The relation between LAEP scores with other epidemiological variables was also assessed. Results: Our study found a positive correlation between the LAEP and the HADS scores (p = <0.01).
The most common adverse effects were drowsiness (81.5% [n = 106]), difficulty in concentrating (76% [n = 99]), and nervousness and/or agitation (75% [n = 97]). Female gender, a history of febrile seizures, persistent seizures and polytherapy were associated with a higher toxicity on LAEP. In our study, age at epilepsy onset, duration of epilepsy, type of epilepsy and patients' age were not related to higher LAEP scores. Conclusion: Adverse effects to AEDs can be related with the presence of psychiatric disorders such as anxiety and depression in patients with epilepsy.
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The main objective of this study was to apply the Spanish version of the Liverpool Adverse Event Profile (LAEP) in Mexican patients diagnosed with epilepsy in the Epilepsy Clinic of Mexico's National Institute of Neurology and Neurosurgery (NINN) and its relation to the presence of anxiety and/or depression measured by The Hospital Anxiety and Depression Scale (HADS).
Materials and methods

Subject selection
LAEP and HADS surveys were applied on 130 consecutive adult patients (age > 18) diagnosed with epilepsy using the ILAE 1989 classification 6 ; patients were clinically assessed at the Epilepsy Clinic of the NINN from March through September 2011. Patients, who were illiterate and those who had severe cognitive problems or had a neurological or mental condition that would not allow them to fill the evaluation scales were excluded. The study was first approved by the Institute's Research and Ethics Committees. This version has a Cronbach's alpha coefficient of 0.90 for the full scale, 0.84 for the depression subscale and 0.85 for the anxiety subscale. The cut-off point for depressive disorder is 5 (sensitivity 77.8%; specificity 80.9%), and for anxiety disorder is 8 (sensitivity 89%; specificity 77.2%).
Data collection
Socio-demographic data were collected including age, gender, educational level, employment status, age at seizure onset, diagnosis (type of epilepsy); persistent seizure type; months free of any seizure type; seizure freedom (the definition of the ILAE consensus by the Commission on Therapeutic Strategies Level 1, 12 was used to determine response to treatment; where seizure freedom was defined as freedom from all types of seizures including auras or simple partial seizures for 12 months; treatment failure the outcome whereby the patient did not attain seizure freedom after an informative trial of an intervention and undetermined for patients that do not fulfill the seizure freedom or the treatment failure categories, for example patients free of seizures for at least one month but less than 12 months); family history of epilepsy, malformation/congenital defect, cerebral hypoxia, head trauma, febrile seizures, neuroinfection, cerebrovascular disease or unknown conditions [none of the former]); current treatments (including AEDs and use of antidepressant and/ or anxyolitic drugs). Patients were also directly asked if they had any difficulties understanding any of the scales items.
Statistical analysis
Data were analyzed using the SPSS 1 (Statistical Package for Social Sciences -version 17) software. Central tendency measures and percentages were used for the descriptive analysis of continuous and nominal variables, respectively. Comparisons were established using the x 2 test or the exact Fisher test for categorical variables and Student's t test or Mann-Whitney U test for numerical variables. We performed a correlation analysis (Spearman) between ratings of the LAEP and the anxiety and depression scores of the HADS. Comparisons between AEDs in mono and polytherapy, LAEP and HADS scores using KruskalWallis one-way analysis of variance were also done.
Results
Socio-demographic and clinical characteristics
Data were collected from 130 patients (54% women, [n = 60]); mean age was 30.6 AE 11.08 years. Regarding educational level, 20.8% (n = 27) patients had finished primary school, 24.6% (n = 32) had attended secondary school, 25.4% (n = 33) had finished high school and 29.2% (n = 38) had a college degree. Paid employees constituted 30.8% (n = 40) of the population, 9.2% (n = 12) were unemployed and 36.2% (n = 47) were employed without payment, e.g. housekeepers. Mean age at seizure onset was 15.0 AE 10.71 years (range 1-65 years). Mean duration of epilepsy was 15.57 years. Forty three patients (33.3%) had a family history of epilepsy and 4.5% (n = 9) had experienced febrile seizures.
Sixty seven patients (51.5%) had cryptogenic epilepsy, 29.2% (n = 38) had symptomatic epilepsy and 19.2% (n = 25) had idiopathic epilepsy. Sixteen patients (12.3%) had mesial temporal lobe epilepsy due to hippocampal sclerosis (MTLE/HS) and in the analysis were considered cryptogenic. Among patients with symptomatic epilepsies, 8.5% (n = 11) had congenital malformation or focal dysplasia, 7.7% (n = 10) had cerebrovascular disease, 6.9% (n = 9) had history of neuroinfection, 3.1% (n = 4) had neoplasia, 2.3% (n = 3) had phacomatosis and 1% (n = 1) presented cerebral hypoxia. Six patients with MTLE/HS and eight patients with neoplasia had had epilepsy surgery. Patients with symptomatic epilepsies due to neoplasia and those with persistent seizures were under study to determine if they were surgical candidates. Among patients with idiopathic epilepsies, 14.6% (n = 19) patients had juvenile myoclonic epilepsy, 2.3% (n = 3) had epilepsy with tonic-clonic seizures on awakening and one patient had juvenile absence epilepsy.
Two patients were diagnosed with Lennox-Gastaut syndrome, but had a mild cognitive defect, so they were able to complete the surveys with the supervision of a relative.
Twenty four patients (18.5%) were seizure free; 68 patients (52.3%) persisted with seizures and 38 patients (29.2%) were undetermined regarding seizure control. The persistent seizure types were: complex partial seizures (CPS) in 24.6% (n = 32) patients, followed by generalized tonic-clonic seizures in 16.2% (n = 21) patients, simple partial seizures (SPS) in 13.8% (n = 18) patients, myoclonic seizures in 13.1% (n = 17) patients, secondarily generalized partial seizures (SGPS) in 8.5% (n = 11) patients, absence seizures in 1.5% (n = 2) patients and other seizures types in 4.5% (n = 6) patients.
Sixteen patients (12.3%) received antidepressant or anxyolitic treatment in a regular manner, without exceeding a 12-month period of time.
LAEP and HADS scores
The most common AEs were: drowsiness 81.5% (Fig. 1) . The average LAEP score was 41.2 AE 11.8 (SD) with a minimum of 19 and a maximum of 66. The mean value for the HADS depression subscale (HADS-D) was 4.56 AE 3.98 (SD), (range 0-19). The mean value for the HADS anxiety subscale (HADS-A) was 7.40 AE 4.25 (SD), (range 0-21). Table 1 shows the toxicity rate in the LAEP, using a cut-point score of <45 for ''low toxicity'' and !45 for ''high toxicity'' as previously described by Gilliam et al. 5 and also shows the correlation between HADS-D and HADS-A with the toxicity scores of LAEP where a positive correlation was found between the depression and anxiety scores from HADS (r = 0.639; p = <0.01). A positive correlation was also found between the depression severity score (HADS-D) and the LAEP score (r = 0.55; p = <0.01); and with the HADS-A score and the LAEP scale rates (r = 0.59; p = <0.01) (Fig. 2) .
3.3.
Comparisons between clinical characteristics with LAEP and HADS subscales (see Table 2 )
When LAEP and HADS scores were compared for men and women, a statistically significant difference in gender was observed, as women had higher toxicity on LAEP score (p = 0.034).
Depression was more frequent in patients with symptomatic epilepsy, while anxiety was seen more in patients with idiopathic epilepsy but there were no significant differences in LAEP toxicity scores between patients considering epilepsy etiology (p = 0.089). No significant differences were found when the HADS-D and HADS-A scores were compared among patients with cryptogenic, idiopathic and symptomatic epilepsy (p = 0.36 and p = 0.48, respectively).
Patients with persistent seizures and undetermined regarding seizure control had significantly higher toxicity scores than those free from all seizures (p = 0.004) whereas HADS-D and HADS-A scores were not related to seizure freedom (p = 0.256 and p = 0.267, respectively).
Patients with history of febrile seizures, presented a higher toxicity LAEP (p = 0.033) compared to those without them; neither HADS-D nor HADS-A had statistically significant differences in this group (p = 0.58 and p = 0.33, respectively).
No statistically significant differences were found regarding high toxicity measured by LAEP and HADS-D or HADS-A when considering age at epilepsy onset (p = 0.80; p = 0.51; p = 0.94), duration of epilepsy (p = 0.153; p = 0.88; p = 0.38) and patients' current age (p = 0.182; p = 0.91; p = 0.36).
There was a statistically significant relation (see Table 2 ), as well as a positive correlation between the number of AEDs and LAEP toxicity scores (r = 0.29; p = 0.001).
Patients taking antidepressants or anxyolitics had higher LAEP toxicity, HADS-D and HADS-A scores (p = 0.028; p = <0.01; p = 0.01); 31.3% (n = 5) of these patients had a relevant HADS-D score and 62.5% (n = 10) had a relevant HADS-A score, nine of these patients (56.3%) were taking two or three AEDs and only one patient (6.3%) was completely seizure free, three patients (18.8%) were undetermined regarding seizure control and 12 patients (75%) had treatment failure and persisted with seizures.
Determination of antiepileptic drugs in mono and polytherapy and their relation to LAEP score
Over half of patients were on AED monotherapy (53.1% [n = 69]), 22.3% (n = 29) patients received two AEDs, 20.8% (n = 27) patients used three AEDs, and 3.8% (n = 5) received four AEDs. Most commonly used AEDs in monotherapy were: valproate (VPA) in 29 patients, carbamazepine (CBZ) in 15 patients and phenytoin (PHT) in six patients.
Valproate was the most commonly used AED in polytherapy (40 patients), followed by CBZ in 30 patients, and lamotrigine (LTG) in 18 patients. The most frequent AEDs combinations were: VPA + CBZ in 6.6% (n = 4) of patients, PHT + CBZ in 6.6% (n = 4) patients, VPA + CBZ + PHT in 6.6% (n = 4) patients and VPA + LTG in 4.9% (n = 3) patients.
Comparisons between each AED in monotherapy and all AEDs in polytherapy did not show a statistically significant difference in LAEP score (p = 0.28) and HADS subscales (p = 0.46) as shown in Fig. 3 . Table 3 shows the percentage of use in monotherapy, as well as in polytherapy of the various AEDs.
When the association between AEs and LAEP scores was studied for each AED used in mono and polytherapy, tremor produced by VPA monotherapy was the only AE that showed statistical significance (p = <0.01). Mouth and gum problem was the only AE that showed statistical significance with CBZ polytherapy (p = <0.01). 
Discussion
The LAEP scale was used to study common adverse events produced by AEDs in patients diagnosed with epilepsy who attended the Epilepsy Clinic in a referral neurological healthcare institution. LAEP scores were correlated with the presence of anxiety and/or depression using the HADS subscales scores.
Our study found a significant correlation between anxiety and/ or depression symptoms severity according to HADS subscales and high toxicity (!45) on LAEP scale in patients with epilepsy (p = <0.01). Thus, it can be deduced that a higher LAEP score (a higher AE frequency and severity) can be correlated with the presence of psychiatric disorders such as anxiety and depression. Similar findings have been reported in previous studies using the LAEP scale. 8, 9, 13, 14 Mensah et al. 15 studied 515 epilepsy patients that completed the HADS survey; about 18.9% of these patients had mild anxiety and 20.5% presented a significant disorder. In addition suggested that a past and current history of depression are the strongest factors associated with anxiety, and that anxiety disorders commonly affect patients with epilepsy and can be related to the disease itself or to other factors such as demographic and social characteristics. Other studies have estimated that the prevalence of anxiety disorders in patients with epilepsy fluctuates between 14.8% and 25%. 16, 17 In our study, the most common AEs were drowsiness (81.5%), followed by difficulty in concentrating (76%), nervousness (75%), memory problems (74%) and fatigue (73%). These results are consistent with those of previous studies. 18, 19 Only 1.5% (2) of patients did not report any adverse event at all, and none of our patients obtained the maximum score. These results, in accordance to Carreñ o et al.: ''suggest that this survey covers the occurrence of the specific adverse events present in the population under study''. 9 It must be noticed that some patients had some difficulties differentiating the meaning of item 19 ''sleep disturbances'' from the one of item 16 ''drowsiness (being sleepy)''; when they were questioned about their interpretation of item 19 some patients thought they were being asked about having nightmares or insomnia. It also should be pointed out that the Likert Scale used in the LAEP lacks an intermediate category between the values [3] = sometimes and [4] = often or always; this could result in higher scores in some patients.
The use of the LAEP scale was justified due to the fact that some adverse events produced by AEDs, such as diplopia, dysarthria, mood disorders, headache, dizziness, gastrointestinal disorders, dermatological problems, and idiosyncratic reactions can easily be reported by the patient through routine questions; however, drowsiness, cognitive impairment and sexual dysfunction, hair changes, nystagmus, claudication, tremor and weight gain or loss are evident when a standardized questioning method is used. 8, 20 In addition, some of the AEs of AEDs, such as difficulty in concentrating, fatigue and sleep disorders, can resemble some somatic symptoms of depression. 21 These confusing factors can alter the sensitivity and specificity of a differential tool such as the LAEP scale, emphasizing the importance of using a concomitant assessment tool that can clarify these potential confounding factors.
Neither AED in monotherapy nor AEDs in polytherapy were associated with a significantly higher score on LAEP or HADS subscales. When AEDs in mono and polytherapy were correlated with each AEs of the LAEP scale; VPA monotherapy was found to significantly correlate with the presence of tremor, a commonly side effect described with this AED and CBZ polytherapy significantly correlated with mouth and gum problems possibly because it was frequently combined with PHT.
Perucca et al. 14 reported that seizure onset at a young age; symptomatic etiology and a history of febrile seizures had a negative impact on LAEP scores. We found that 77.8% of patients with febrile seizure presented a LAEP score !45 (p = 0.033), probably related to drug-resistant temporal lobe epilepsy. We also found that female gender showed higher LAEP toxicity and HADS-A score. In our study, age at seizure onset, epilepsy duration and etiology did not have a statistically significant relationship to LAEP toxicity; a recent study by Martins et al. 22 found no differences in LAEP scores in patients with focal and generalized epilepsies. Treatment failure or the presence of persistent seizures was frequent among our patients as we are a referral center and we used the new ILAE consensus to determine seizure freedom; these could be the reasons why only 18.5% patients were completely free of all seizures. Patients with persistent seizures showed higher LAEP toxicity but interestingly not significantly higher scores on HADS subscales. It could be that patients with persistent seizures were taking more than one AED thus patients on polytherapy had a significantly higher toxicity on LAEP. Several studies have suggested a correlation between AED polytherapy and a low quality of life score in patients with epilepsy. [23] [24] [25] Although our patients did not complete a quality of life survey, a positive correlation was found between the number of AEDs that they received and the LAEP score. Canevini et al. 26 suggested that AEDs' toxicity is more closely related to the total ''load'' of the drug (the sum of all ratios of actually prescribed daily doses and the mean therapeutic dose of each drug) than to the number of administered AEDs; however they found no correlation between LAEP and AEDs' load in a group of patients with drug-resistant epilepsy but a positive correlation between LAEP and number of AEDs. These authors concluded that ''the current tendency to refuse polytherapy because of a concern of increased toxicity is not warranted''. They also suggested that the LAEP had a suboptimal sensitivity as a tool for the detection of differences in the toxicity of AEDs in varying patient cohorts. Panelli et al. 8 did not find statistically significant differences when average LAEP scores were compared in three different groups of patients: without AEDs, with AEDs, and with recently initiated AED therapy. We consider that high LAEP scores in our patients in monotherapy might be the result of the presence of anxiety and/or depression disorders and possibly a reflect of genetic variability; the latter could be responsible for 20-95% variance in the response to AEDs, and could also affect the drugs tolerability and safety. 27 Unfortunately, current pharmacological treatment for epilepsy, in contrast with other therapeutic fields, is not a ''clearly'' outlined process in which a specific functional o biochemical deficit is corrected, thus, selecting an AED is an empirical process based on previous clinical observations made with representative patients, 28 as we found polytherapy can lead to high LAEP toxicity and not necessarily to seizure freedom. Kanner et al. 29 in a study with 188 patients with an epilepsy diagnosis, showed that mood disorders and/or anxiety often go underrecognized and undertreated, considering that up to 64.7% of symptomatic cases had not received any treatment and only 28% of patients who received antidepressants were free of symptoms; about 72% still had some symptoms that were partially due to suboptimal antidepressant prescription. These findings are similar to ours, where 12.3% (n = 16) of patients received antidepressants or anxyolitics in a regular manner without exceeding the 12-month treatment course; among these patients 31.3% had a high HADS-D score and 62.5% had a high HADS-A score; it should be pointed out that these patients were mainly on AED polytherapy and most of them persisted with seizures, which could also explain the high LAEP toxicity seen in this group.
Conclusions
The importance of this study lies in the fact that it is the first one to apply the Spanish validated LAEP scale to Mexican patients with epilepsy and correlates its results to anxiety and depression symptoms measured with the HADS scale.
Our study was limited by the fact that AEs cannot be assessed through LAEP in patients that are not able to answer the survey (i.e. patients with moderate or severe cognitive impairment or patients who are illiterate), a factor that could cause our results to be biased. As this was a descriptive cross-sectional study it did not allow the assessment of AEs when AEDs dosages were changed and/or antidepressant or anxiolytic drugs were initiated.
The results shown can only be analyzed in terms of relations and not of causality, because both surveys were applied in a certain moment during the disease, that is, we cannot determine if anxiety or depression disorders trigger a certain number of AEs, or if the presence of AEs has any incidence on the severity of anxiety/ depression. This study was carried out in a highly specialized hospital, where the majority of the patients presents difficult to control epilepsies; therefore, our results cannot be extrapolated for the rest of the Mexican patients with epilepsy.
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